The burden of pneumococcal disease among adults in developed and developing countries: what is and is not known.
about
The impact and effectiveness of pneumococcal vaccination in Scotland for those aged 65 and over during winter 2003/2004Vaccines for preventing pneumococcal infection in adultsVaccines for preventing pneumococcal infection in adultsPneumococcal vaccine and patients with pulmonary diseasesPneumonia in South-East Asia Region: public health perspectiveGenome analysis of a highly virulent serotype 1 strain of Streptococcus pneumoniae from West AfricaPneumococcal pili are composed of protofilaments exposing adhesive clusters of Rrg ABurden of pneumonia and meningitis caused by Streptococcus pneumoniae in China among children under 5 years of age: a systematic literature reviewProtective contributions against invasive Streptococcus pneumoniae pneumonia of antibody and Th17-cell responses to nasopharyngeal colonisationInsights into the interaction between influenza virus and pneumococcusObesity, diabetes and pneumonia: the menacing interface of non-communicable and infectious diseases.African meningitis belt pneumococcal disease epidemiology indicates a need for an effective serotype 1 containing vaccine, including for older children and adultsPneumococcal carriage results in ganglioside-mediated olfactory tissue infection.The burden of common infectious disease syndromes at the clinic and household level from population-based surveillance in rural and urban KenyaInvasive pneumococcal infections in Denmark from 1995 to 1999: epidemiology, serotypes, and resistance.Carriage of Streptococcus pneumoniae and other respiratory bacterial pathogens in low and lower-middle income countries: a systematic review and meta-analysis.Invasive serotype 1 Streptococcus pneumoniae outbreaks in the South Pacific from 2000 to 2007.Estimating the proportion of pneumonia attributable to pneumococcus in Kenyan adults: latent class analysis.Age-specific immunoglobulin g (IgG) and IgA to pneumococcal protein antigens in a population in coastal kenya.Issues in the design and implementation of vaccine trials in less developed countries.Current state of pneumococcal vaccines.Challenges of using molecular serotyping for surveillance of pneumococcal disease.Optimising assessments of the epidemiological impact in The Netherlands of paediatric immunisation with 13-valent pneumococcal conjugate vaccine using dynamic transmission modelling.Streptococcus pneumoniae meningitis in Alberta pre- and postintroduction of the 7-valent pneumococcal conjugate vaccine.Comparative immune responses of patients with chronic pulmonary diseases during the 2-year period after pneumococcal vaccination.Consensus Recommendation for India and Bangladesh for the Use of Pneumococcal Vaccine in Mass Gatherings with Special Reference to Hajj Pilgrims.Serotype-specific and age-dependent generation of pneumococcal polysaccharide-specific memory B-cell and antibody responses to immunization with a pneumococcal conjugate vaccine.The multidrug-resistant PMEN1 pneumococcus is a paradigm for genetic success.Estimating rates of carriage acquisition and clearance and competitive ability for pneumococcal serotypes in Kenya with a Markov transition model.Serotype-specific problems associated with pneumococcal conjugate vaccination.Pneumonia's second wind? A case study of the global health network for childhood pneumoniaOptimization and validation of a multiplex, electrochemiluminescence-based detection assay for the quantitation of immunoglobulin G serotype-specific antipneumococcal antibodies in human serumInduction of pro- and anti-inflammatory molecules in a mouse model of pneumococcal pneumonia after influenza.Preventing pneumococcal disease in the elderly: recent advances in vaccines and implications for clinical practice.Vaccines for children and adults with chronic lung disease: efficacy against acute exacerbations.Immunization with polyamine transport protein PotD protects mice against systemic infection with Streptococcus pneumoniae.Pneumococcal conjugate vaccine use in adults.Cost Effectiveness of Pneumococcal Vaccination in Children in Low- and Middle-Income Countries: A Systematic Review.Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive disease and hospital-treated pneumonia among people aged ≥65 years: a retrospective case-control study.Diagnosis of pneumococcal pneumonia by psaA PCR analysis of lung aspirates from adult patients in Kenya
P2860
Q21261529-F0989B63-33CE-4551-8CB6-AE5E704AD147Q24201474-D90D5A0A-B80A-4B61-BD4C-89FAFFAF064EQ24242290-7ABBCAF0-6694-49D0-8ABB-EAEA8CF243C1Q26825944-5EA3D3D8-10C2-4D51-8DDF-E344BB40171CQ27027095-CD614FDA-90FE-46D5-A723-1F8307240ECFQ27315098-895F4DFB-6098-4407-8D50-2E819F39BB60Q28472283-02E322A8-C968-47C6-A6C3-03F53736DC5BQ28742681-3ACEB03C-5CC4-4901-90A8-3227BF4EED0BQ28744146-CE8240C2-26AD-408A-A2A1-7573080F39C2Q30355570-642B66BB-E842-423F-9DD5-ACE2D253062FQ30355645-C6341996-A8C8-4ECC-9C0A-5B8AE6DA1D09Q33530554-7EADA530-A915-47B2-8C96-8761ECEE6D4CQ33717128-90E21D92-DF95-4D52-9BDC-8CC655CB83BEQ33803895-FA3B6E94-8250-43BB-A9D3-3BF9101BC477Q33942204-B193AE14-1697-4BB2-B02C-D78F5EEFF163Q33988997-414F42EB-87C5-419A-A680-AA6215B705B0Q34046326-6962491F-E18A-4B53-8AC5-F99C7FC8D3C5Q34071298-BE758E51-7A39-4DD9-A165-6782A745F849Q34145758-03D14FDF-C96E-423E-896E-D455053DAB44Q34578596-95CF0C9D-7E42-451C-83A1-853F33B6F8A8Q34744239-499EB9C5-B337-453C-80D1-1EF100C963EEQ35035741-EDBD3791-99D3-4CDD-8E8E-9A3B0AA3FB33Q35138184-F6821B1E-4E07-4758-9B5D-766E274D158FQ35569198-904D38B7-9C5F-4600-8800-AFBABF0CA86AQ35636112-7D736CC5-7E28-4635-9777-9808F160FF20Q36220236-CE4AB7C5-C65F-4E1D-A801-97833F2594EBQ36452316-49F596EB-587E-4B56-A509-73705E44052CQ36633083-3129270C-ADF5-4F14-86B4-670C89782124Q36894814-87307540-AD7C-4098-BD87-8F7488D053E4Q37071137-BC9E43DC-893C-4CAB-A101-6D9AAD68C8C7Q37111997-1CF16744-C0DE-44FB-8D22-194DA0A41A59Q37116583-F01A8C4D-57C7-440B-A1E6-59BBE3C455B9Q37330594-B429DC5A-68F3-450B-B4D7-946151ED6CA0Q38082673-6244A34F-C223-4FE8-9BE0-FB173435F9DDQ38168915-DF77E26F-E3EE-49F1-8E80-BF4D3FFA9E6AQ38486051-CED85ACB-F5E4-4257-B188-3054CA3DCC49Q38664425-888A4EE3-3282-4B0D-9364-59D7C1F29B22Q38924170-B0E42A71-0DC2-40A3-91C9-5D19A662D868Q39041235-F46F7A5C-820B-40D8-AEFC-795ED912BCADQ39758031-E1259D64-39B5-43B0-98F0-B942BAF9B71A
P2860
The burden of pneumococcal disease among adults in developed and developing countries: what is and is not known.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
The burden of pneumococcal dis ...... ies: what is and is not known.
@ast
The burden of pneumococcal dis ...... ies: what is and is not known.
@en
type
label
The burden of pneumococcal dis ...... ies: what is and is not known.
@ast
The burden of pneumococcal dis ...... ies: what is and is not known.
@en
prefLabel
The burden of pneumococcal dis ...... ies: what is and is not known.
@ast
The burden of pneumococcal dis ...... ies: what is and is not known.
@en
P1433
P1476
The burden of pneumococcal dis ...... ies: what is and is not known.
@en
P2093
P356
10.1016/S0264-410X(99)00122-X
P407
P478
17 Suppl 1
P577
1999-07-01T00:00:00Z